共 50 条
Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review
被引:16
|作者:
Van Der Weijst, Lotte
[1
]
Lievens, Yolande
[1
]
Schrauwen, Wim
[2
]
Surmont, Veerle
[3
]
机构:
[1] Ghent Univ Hosp, Dept Radiotherapy Oncol, Ghent, Belgium
[2] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
[3] Ghent Univ Hosp, Dept Thorac Oncol, Ghent, Belgium
来源:
FRONTIERS IN ONCOLOGY
|
2019年
/
9卷
关键词:
quality of life;
review-systematic;
lung cancer;
methodological quality;
NSCLC;
RANDOMIZED PHASE-III;
DOCETAXEL PLUS CISPLATIN;
COMPREHENSIVE GERIATRIC ASSESSMENT;
PATIENT-REPORTED OUTCOMES;
COMPARING PACLITAXEL POLIGLUMEX;
GEFITINIB MAINTENANCE THERAPY;
PLATINUM-BASED CHEMOTHERAPY;
TREATED JAPANESE PATIENTS;
SINGLE-AGENT GEMCITABINE;
ELDERLY-PATIENTS;
D O I:
10.3389/fonc.2019.00715
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-related quality of life (HRQoL). Advanced NSCLC trials with HRQoL endpoints face methodological constraints limiting interpretability. Objectives: We provide a comprehensive overview of recent clinical trials evaluating the impact of systemic therapies on HRQoL in advanced NSCLC, focusing on the methodological quality, with the ultimate goal to improve interpretation, comparison and reporting of HRQoL data. Methods: A systematic literature review was performed. Prospective studies published over the last decade evaluating the impact of systemic treatments on HRQoL in advanced NSCLC were included. Methodological quality of HRQoL reporting was assessed with the CONSORT-PRO extension. Results: Hundred-twelve manuscripts describing 85 trials met all criteria. No formal conclusion can be drawn regarding the impact on HRQoL of different treatments. We report an important variety in methodological quality in terms of definitions of HRQoL, missing data points, lack of standardization of analyzing and presenting HRQoL and no standard follow-up time. The quality of HRQoL data reporting varies substantially between studies but improves over time. Conclusion: This review shows that in the heterogeneous landscape of trials addressing HRQoL in advanced stage NSCLC. Methodology reporting remains generally poor. Adequate reporting of HRQoL outcome data is equally important to support clinical decision-making as to correctly inform health policy regarding direct approval and reimbursement of the new drugs and combinations that will come online.
引用
收藏
页数:13
相关论文